Although DPP-4 inhibitors/GLP-1 RAs have been widely used in T2DM patients worldwide, there is a concern about AEs, as the Savor-TIMI 53 trial reported that saxagliptin increased the rate of hospitalization for HF [34]. The gene discussed is DPP4; the disease is hydrops fetalis.